This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Drug Interactions With Newer Antidepressants: Role of Human Cytochromes P450

David J. Greenblatt, M.D.; Lisa L. von Moltke, M.D.; Jerold S. Harmatz; and Richard I. Shader, M.D.

Published: April 1, 1998

Article Abstract

Selective serotonin reuptake inhibitors and related antidepressant compounds have the secondarypharmacologic property of inhibiting the activity of human cytochrome P450 enzymes responsible forthe oxidative metabolism of many drugs. A number of clinically important pharmacokinetic drug interactionsare a consequence of these cytochrome inhibiting effects. This review evaluates the clinicalimplications of the metabolic profiles of the newer antidepressants, the relative activities of variousnew antidepressants as inhibitors of human cytochrome P450, and the various in vivo and in vitromethodologies that can be used for identification and quantification of drug interactions.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: